focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 7.375
High: 7.375
Low: 7.375
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO plc announces SBRI Healthcare contract

16 Apr 2014 07:00

RNS Number : 9231E
IXICO plc
16 April 2014
 



16 April 2014

 

 

IXICO plc announces SBRI Healthcare development contract

 

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, announces that it has been awarded a development contract by SBRI Healthcare (The Small Business Research Initiative for Healthcare) to cover Phase 1 funding for the development of an online application designed to support dementia sufferers post-diagnosis.

Receiving a dementia diagnosis is inevitably traumatic for patients and far too often, patients and their families receive very little support until there is a crisis. This development project will build on Assessa™, IXICO's digital healthcare platform to support dementia diagnosis, to address post-diagnostic care planning and support. It aims to harness web and mobile technologies to provide ongoing support and to assist those living with dementia as well as their families, carers and healthcare professionals. The goal is to prolong and enhance independent living by facilitating improved self-care with full interaction with the relevant healthcare professionals and other support agencies. Social media concepts will be adapted to build a personal management tool whereby diagnosis is carefully linked to continuing care-planning and support. This will then aid the transition into other care settings by travelling with the patient and relatives throughout the course of the illness.

The project will be led by IXICO in partnership with the Health Innovation Network South London. (www.hin-southlondon.org)

Commenting on the award, Derek Hill, CEO of IXICO said:

 

'We are delighted to receive this support from SBRI Healthcare which will help us to extend the potential patient benefit of Assessa™ following diagnosis and is central to the widening of our digital healthcare offering. We look forward to working with the Health Innovation Network to improve the care of dementia sufferers.'

 

Commenting on the award, Dr Hugo DeWaal, Clinical Director for Dementia at the Health Innovation Network said:

 

'Dementia is a key health and social care priority, and the Health Innovation Network is keen to develop a tool that is helpful for people with dementia, their families and carers. We hope that this partnership and SBRI funding will allow us to rapidly improve dementia care for a greater number of people.'

About SBRI Healthcare

The Small Business Research Initiative for Healthcare (SBRI Healthcare) is an NHS England initiative, championed by the newly formed Academic Health Science Networks (AHSNs), that aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. Part of Innovation Health and Wealth, the SBRI Healthcare programme sets industry the challenge in a series of health related competitions which result in fully funded development contracts between the awarded company and the NHS. Unlike many R&D projects which offer grant or match funding, SBRI contracts are 100 per cent funded and the company retains the IP.

More information is available on www.sbrihealthcare.co.uk

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by nine of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

About the Health Innovation Network

The Health Innovation Network is a membership organisation, driving lasting improvements in health and wellbeing across South London by sharing innovations across the health system and capitalising on teaching and research strengths. Founded by NHS England, the Health Innovation Network is the Academic Health Science Network (AHSN) for South London. We are focusing on health priorities for our local communities across a number of clinical areas and cross-cutting innovation themes, including dementia, diabetes, musculoskeletal, alcohol and cancer. www.hin-southlondon.org 

 

Enquiries:

 

IXICO plc

Derek Hill, CEO

Charles Spicer, VP Corporate Development

+44 20 7691 2064

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

 

Daniel Stewart & Company (Joint Broker)

Mark Treharne

David Hart

+44 207 776 6550

 

FTI Consulting Limited (Investor Relations)

Ben Atwell

Simon Conway

John Dineen

+44 20 3727 1000 

 

Health Innovation Network

Anna King, Commercial Director

+44 20 7188 7188

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFDEDIFLSEFL
Date   Source Headline
29th Aug 201312:01 pmRNSSchedule 1 update - Phytopharm plc
9th Aug 20137:00 amRNSInterim Management Statement
8th Aug 201312:23 pmRNSSchedule 1 update - Phytopharm plc
8th Aug 201311:00 amRNSChange to AIM Admission Timetable
6th Aug 20132:15 pmRNSSchedule 1 - Phytopharm plc
5th Aug 20132:16 pmRNSResult of General Meeting
19th Jul 201311:06 amRNSCancellation of Listing and Admission to AIM
23rd May 20137:00 amRNSInterim Results
21st May 20137:45 amRNSStatement re. Suspension
21st May 20137:30 amRNSTemporary Suspension - Phytopharm Plc
17th May 20139:23 amRNSNotice of Results
27th Mar 201310:15 amRNSAGM Statement
26th Mar 20137:00 amRNSStrategic Review Update
15th Mar 201312:06 pmRNSHolding(s) in Company
18th Feb 20137:00 amRNSResearch Update
13th Feb 20131:59 pmRNSHolding(s) in Company
5th Feb 20137:00 amRNSInterim Management Statement
4th Feb 201311:34 amRNSNotice of AGM
19th Dec 20129:21 amRNSAnnual Financial Report
18th Dec 20127:00 amRNSCogane in ALS Update
17th Dec 201211:00 amRNSBlocklisting Interim Review
22nd Nov 20127:00 amRNSPreliminary Results
9th Nov 20121:32 pmRNSNotice of Results
5th Nov 20121:00 pmRNSBlocklisting Interim Review
17th Oct 20125:27 pmRNSBlocklisting Interim Review
1st Oct 201211:44 amRNSTotal Voting Rights
26th Sep 20127:00 amRNSHolding(s) in Company
31st Aug 20124:40 pmRNSSecond Price Monitoring Extn
31st Aug 20124:35 pmRNSPrice Monitoring Extension
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
16th Aug 20127:00 amRNSInterim Management Statement
18th Jun 20129:59 amRNSBlocklisting Interim Review
30th May 20127:00 amRNSHalf Yearly Report
11th May 20127:00 amRNSResearch Update
3rd May 201211:46 amRNSNotice of Results
3rd May 20129:54 amRNSBlocklisting Interim Review
18th Apr 20127:00 amRNSResearch Update
18th Apr 20127:00 amRNSResearch Update
11th Apr 201211:08 amRNSBlock Listing Application
29th Mar 20127:00 amRNSDirectorate Change
28th Mar 20129:35 amRNSResult of AGM
24th Feb 20127:00 amRNSNotice of AGM
16th Feb 20127:00 amRNSInterim Management Statement
14th Feb 20129:34 amRNSHolding(s) in Company
6th Feb 20129:25 amRNSAnnual Information Update
2nd Feb 20127:00 amRNSDirectorate Change
27th Jan 201210:17 amRNSAnnual Financial Report
16th Jan 20127:00 amRNSResearch Update
11th Jan 20123:53 pmRNSBlocklisting Interim Cancellation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.